Stockscreener 앱 받기
10.00
0.70%
0.07
시간 외 거래:
10.00
전일 마감가:
$9.93
열려 있는:
$9.8
하루 거래량:
1.25M
Relative Volume:
0.52
시가총액:
$1.79B
수익:
$15.36M
순이익/손실:
$-276.48M
주가수익비율:
-6.20
EPS:
-1.6129
순현금흐름:
$-235.87M
1주 성능:
-5.21%
1개월 성능:
+12.87%
6개월 성능:
+114.59%
1년 성능:
+199.40%
1일 변동 폭
$9.66
$10.22
1주일 범위
$9.66
$11.49
52주 변동 폭
$1.775
$11.49
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
10.00 | 1.77B | 15.36M | -276.48M | -235.87M | -1.6129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-04-17 | 개시 | Wells Fargo | Equal Weight |
| 2024-09-10 | 재개 | Goldman | Buy |
| 2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
Relay Therapeutics (RLAY) — Perceptive entities report 5.3% stake - Stock Titan
Nextech Invest Increases Relay Therapeutics Stake in Q4 2025 | Portfolio UpdateNews and Statistics - IndexBox
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - The Motley Fool
Relay Therapeutics (RLAY) Receives a Buy from Wells Fargo - The Globe and Mail
Portfolio Update: Is Relay Therapeutics Inc a speculative investmentEarnings Growth Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
RLAY: Citizens Raises Price Target to $17, Maintains Market Outp - GuruFocus
Relay Therapeutics price target raised to $17 from $15 at Citizens - TipRanks
RLAY: Citizens Raises Price Target to $17, Maintains Market Outperform Rating | RLAY Stock News - GuruFocus
Citizens Jmp Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Relay Therapeutics (RLAY) Sees Price Target Raised by Wells Farg - GuruFocus
Wells Fargo & Company Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00 - MarketBeat
Oppenheimer reiterates Relay Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Relay Therapeutics (RLAY) Unveils Promising Phase 1/2 Trial Resu - GuruFocus
Relay Therapeutics Reports Promising Phase 3 Data for Zovegalisib + Fulvestrant in PI3Kα-Mutated HR+/HER2- Metastatic Breast Cancer at ESMO TAT 2026 12 - Minichart
Relay Therapeutics Sees Unusually Large Options Volume - National Today
Relay Therapeutics Sees Unusually Large Options Volume (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free SurvivalWhat Does This Means For Pretreated Breast Cancer Patients? - Benzinga
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 - Bitget
Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data - TipRanks
Relay Therapeutics Announces Data from Zovegalisib Plus Fulvestrant At the Phase 3 Dose of 400Mg BID Fed - marketscreener.com
Relay Therapeutics reports 11.1-month median PFS for zovegalisib 400mg BID fed in PI3Kα-mutant MBC - TradingView
Relay Therapeutics (RLAY) shows 11.1-month PFS with zovegalisib combo in PI3Kα-mutated breast cancer - Stock Titan
Relay Therapeutics moves ReDiscover regimen with zovegalisib and fulvestrant to Phase 3 trial - Traders Union
Experimental Relay cancer drug combo shows 11.1-month progression-free survival - Stock Titan
Commodore Capital Boosts Stake in Relay Therapeutics - National Today
Commodore Capital LP Raises Stake in Relay Therapeutics, Inc. $RLAY - MarketBeat
Should Relay’s Zovegalisib Momentum and New Legal Forum Rules Require Action From Relay Therapeutics (RLAY) Investors? - simplywall.st
Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Guggenheim Issues Positive Forecast for Relay Therapeutics (NASDAQ:RLAY) Stock Price - MarketBeat
Guggenheim Raises Price Target for Relay Therapeutics (RLAY) to $22 | RLAY Stock News - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY) - The Globe and Mail
Can Relay Therapeutics Inc expand into new markets2026 Market Sentiment & Growth Focused Stock Reports - baoquankhu1.vn
Relay Therapeutics Files Amended and Restated Bylaws with SEC – Key Company Information and Filing Details - Minichart
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Thomas Catinazzo Sells Shares of Relay Therapeutics Inc (RLAY) - GuruFocus
Relay Therapeutics Updates Bylaws on Federal Securities Litigation - TipRanks
Relay Therapeutics (RLAY) CFO sells 17,717 shares under 10b5-1 plan - Stock Titan
Relay Therapeutics (NASDAQ: RLAY) sets federal courts for securities claims - Stock Titan
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Zovegalisib Milestones To Shape The Future Of Relay Therapeutics - RTTNews
Investment Review: Can Relay Therapeutics Inc sustain its profitability2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
A Look At Relay Therapeutics (RLAY) Valuation After Earnings Update And New Shelf Registration - Sahm
Thomas J. Catinazzo sells 15,515 shares (NASDAQ: RLAY) in Form 144 - Stock Titan
Relay Therapeutics Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Wells Fargo Initiates Coverage of Relay Therapeutics (RLAY) with Equal-Weight Recommendation - MSN
Should I add Relay Therapeutics Inc stock to my portfolio2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst - Seeking Alpha
Relay Therapeutics Stock Price Rises 6% - National Today
Relay Therapeutics (NASDAQ:RLAY) Stock Price Up 6%Should You Buy? - MarketBeat
Why Relay Therapeutics (RLAY) Is Up 14.8% After 2025 Beat, FDA Breakthrough Win for Zovegalisib - Sahm
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):